Literature DB >> 15337214

Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial.

R Christopher Jones1, Gary S Francis, Michael S Lauer.   

Abstract

OBJECTIVES: We identified predictors of mortality in patients with preserved ejection fraction (EF) and clinical heart failure (HF).
BACKGROUND: Although diastolic HF is common, the factors that predict mortality have not been clearly defined.
METHODS: We studied 988 patients with HF and preserved EF enrolled in the Digitalis Investigation Group (DIG) trial. Survival analyses were employed to identify variables associated with mortality.
RESULTS: During 3.1 years of follow-up, 231 (23%) patients died. Among 18 variables considered, the strongest independent predictors of death were glomerular filtration rate (adjusted hazard ratio for one standard deviation decrease 1.50, 95% confidence interval [CI] 1.35 to 1.67, p < 0.0001), New York Heart Association functional class III or IV (adjusted hazard ratio 1.64, 95% CI 1.20 to 2.18, p = 0.0011), male gender (adjusted hazard ratio 1.71, 95% CI 1.26 to 2.32, p = 0.0005), and older age (adjusted hazard ratio for one standard deviation increase of age2 1.28, 95% CI 1.08 to 1.50, p = 0.0019). A risk score was developed to estimate long-term mortality.
CONCLUSIONS: Diastolic HF is associated with a high death rate. Important predictors of death include impaired renal function, worse functional class, male gender, and older age.

Entities:  

Mesh:

Year:  2004        PMID: 15337214     DOI: 10.1016/j.jacc.2004.05.077

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Exercise intolerance.

Authors:  Dalane W Kitzman; Leanne Groban
Journal:  Heart Fail Clin       Date:  2008-01       Impact factor: 3.179

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

3.  American Society of Nephrology Quiz and Questionnaire 2015: Transplantation.

Authors:  Michelle A Josephson; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 8.237

4.  Exercise intolerance.

Authors:  Dalane W Kitzman; Leanne Groban
Journal:  Cardiol Clin       Date:  2011-08       Impact factor: 2.213

Review 5.  Diastolic stress test for the evaluation of exertional dyspnea.

Authors:  Garvan C Kane; Jae K Oh
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

6.  Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.

Authors:  Barry A Borlaug; Margaret M Redfield
Journal:  Circulation       Date:  2011-05-10       Impact factor: 29.690

7.  Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study.

Authors:  Khalil Murad; David C Goff; Timothy M Morgan; Gregory L Burke; Traci M Bartz; Jorge R Kizer; Sarwat I Chaudhry; John S Gottdiener; Dalane W Kitzman
Journal:  JACC Heart Fail       Date:  2015-07       Impact factor: 12.035

Review 8.  Digitalis for treatment of heart failure in patients in sinus rhythm.

Authors:  William B Hood; Antonio L Dans; Gordon H Guyatt; Roman Jaeschke; John J V McMurray
Journal:  Cochrane Database Syst Rev       Date:  2014-04-28

9.  Outcome of heart failure with preserved ejection fraction: a multicentre spanish registry.

Authors:  Juan C Castillo; Manuel P Anguita; Manuel Jiménez
Journal:  Curr Cardiol Rev       Date:  2009-11

10.  Patient sex does not modify ejection fraction as a predictor of death in heart failure: insights from the APPROACH cohort.

Authors:  Heidi N Schmaltz; Danielle A Southern; Colleen J Maxwell; Merril L Knudtson; William A Ghali
Journal:  J Gen Intern Med       Date:  2008-10-02       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.